CAS: 133081-25-1; 6-(2-(Tert-Butoxycarbonyl)Hydrazinyl)Nicotinic Acid

相似化合物

133081-24-0 444794-69-8 163213-19-2

上下游产品

CAS号133081-24-0 6-肼基烟酸 | CAS号24424-99-5 二碳酸二叔丁酯 | CAS号5326-23-8 6-氯烟酸 | CAS号133081-24-0 6-肼基烟酸 | CAS号133081-26-2 2,5-二氧代吡咯烷-1-基6...

6-氯烟酸置于一水合肼,三乙胺体系中,用 N,N-二甲基甲酰胺 用作溶剂,化学反应生成6-[2-(叔丁氧羰基)肼基]烟酸
参考文献:四氢ac啶衍生物作为乙酰胆碱酯酶抑制剂的合成及生物活性
标题:四氢ac啶衍生物作为乙酰胆碱酯酶抑制剂的合成及生物活性
摘要:医学的当前状态不允许治疗神经退行性疾病,例如阿尔茨海默氏病(ad).目前,Ad的治疗受到严格限制.Ad中使用的主要药物是乙酰胆碱酯酶抑制剂(achei),例如他克林,多奈哌齐,加兰他敏和卡巴拉汀,这些都不能促进认知和行为功能的长期改善. 在这项工作中,我们报告了他克林-6-肼基烟酰胺的新杂种的合成和生物学评估.该合成基于他克林衍生物与烟酸肼部分(hynic)之间的缩合反应.所有获得的化合物都对两种胆碱酯酶都具有亲和力,并且相对于丁酰胆碱酯酶(bche)具有高选择性.
Doi:10.1016/j.Bioorg.2011.05.001

专利信息

专利号:US-2024082435-A1
优先权日:2021-02-26
标 题 :Solid phase synthesis of glutamate-urea-lysine derived (GUL derived) prostate-specific membrane antigen (PSMA) targeting conjugates and their use as precursors for therapeutic and/or diagnostic agents
发明人：PINTO ARTUR; BONTEMPS ALEXIS; LEMAIRE LUCAS
权利人:TELIX INT INNOVATIONS PTY LTD
摘要:The disclosure provides methods for the solid phase synthesis of glutamate-urea-lysine derived (GUL derived) prostate-specific membrane antigen (PSMA) targeting conjugates. The disclosure also relates to key intermediates of this process and methods for their preparation such as a method of preparing a compound of formula (V). Also disclosed are use of the conjugates as precursors for therapeutic and/or diagnostic agents, including treating and diagnosing prostate cancer.

专利号:WO-2023091726-A1
优先权日:2021-11-18
标题:Inhibitors of cyclin‑dependent kinase 12 (cdk12)
发明人：BENOIT GUILLAUME; CARULLI JOHN; CHEN FEI; CHUAQUI CLAUDIO; CIBLAT STEPHANE; COOPER ELLIOT; DAGENAIS ROBIN; HU SHANHU; KABRO ANZHELIKA; LAPLACA DEREK; MARINEAU JASON; MOEBIUS DAVID; MOON DIANE; SOLODININ ANDREI; WHITMORE KENNETH
权利人:SYROS PHARMACEUTICALS INC
摘要:The present invention provides chemical compounds that inhibit one or more families of kinases (e.g., serine/threonine kinases, including one or more of the families of CDK proteins, and in particular, CDK12). More specifically, the present invention provides CDK12 inhibitors, of formula (I), pharmaceutically acceptable salts and isotopically labeled derivatives thereof, pharmaceutical compositions containing the compounds/inhibitors, and methods of their synthesis and use in treating proliferative diseases (e.g., a bladder cancer, a breast cancer, Ewing's sarcoma, a gastric cancer, a gastrointestinal cancer, a hematologic cancer, a lung cancer (e.g., small cell lung cancer (SCLC)), an ovarian cancer (e.g., a high grade serous ovarian cancer), a pancreatic cancer (e.g., pancreatic ductal adenocarcinoma (PDAC)), a brain cancer (e.g., glioblastoma), or a prostate cancer), alone or in combination with a second therapeutic agent. The proliferative disease can be a cancer, benign neoplasm, or pathologic angiogenesis, and any of the therapeutic methods or uses described herein can include a step of diagnosing the patient's disease. In other embodiments of the invention, the compositions described herein (e.g., the compounds, pharmaceutical compositions, and kits containing them) are used for the treatment of myotonic dystrophy (type 1 or type 2).

专利号:WO-2022178592-A1
优先权日:2021-02-26
标题 :Solid phase synthesis of glutamate-urea-lysine derived (gul derived) prostate-specific membrane antigen (psma) targeting conjugates and their use as precursors for therapeutic and / or diagnostic agents

专利号:EP-4297804-A1
优先权日:2021-02-26
标题 :Solid phase synthesis of glutamate-urea-lysine derived (gul derived) prostate-specific membrane antigen (psma) targeting conjugates and their use as precursors for therapeutic and / or diagnostic agents

专利号:CN-117355343-A
优先权日:2021-02-26
标题:Solid-phase synthesis of glutamate-urea-lysine-derived (GUL-derived) conjugates targeting prostate-specific membrane antigen (PSMA) and their use as precursors to therapeutic and/or diagnostic agents

专利号:US-7732628-B2
优先权日:2000-03-22
标题 :Functional biopolymer modification reagents and uses thereof
发明人：SCHWARTZ DAVID A; HOGREFE RICHARD I
权利人:SOLULINK INC
摘要:Hydrazino, oxyamino and carbonyl-based reagents and methods for incorporation into oligonucleotides during their solid phase synthesis are provided. Modified oligonucleotides are provided that incorporate the reagents provided herein. Immobilized oligonucleotides and oligonucleotide conjugates that contain covalent hydrazone or oxime linkages are provided. Methods for preparation of surface bound oligonucleotides are provided. Methods for the preparation of oligonucleotide conjugates are also provided.